What question did this study set out to answer?

To establish a reliable gel-filtration assay for measuring distinct circulating forms of tissue factor pathway inhibitor (TFPI) and assess their distribution in hyperlipidemic patients.

April 1, 1995Arteriosclerosis Thrombosis and Vascular BiologyOpen Access

Tissue Factor Pathway Inhibitor Activity in Human Plasma

View Full Paper

Ask AI

Bookmark

Population

19 hyperlipidemic patients (including some receiving plasmapheresis treatment) and normal control subjects

Design

Case-control

Authors

TKToshinori KokawaGuidance (United Kingdom)TATakeo AbumiyaHokkaido University TKTakashi KimuraImperial Household Agency

Discussion

Member takes

Implication

Hyperlipidemia may impair endothelial antithrombotic capacity via TFPI redistribution; hypothesis-generating and should not yet change practice.

Key Points

To establish a reliable gel-filtration assay for measuring distinct circulating forms of tissue factor pathway inhibitor (TFPI) and assess their distribution in hyperlipidemic patients.
Developed a gel-filtration chromatography method using a 1 mol/L NaCl buffer to isolate and quantify free, HDL-associated, and LDL/VLDL-associated plasma TFPI forms.
Assessed TFPI activity in plasma samples from 19 hyperlipidemic patients, including a subset undergoing plasmapheresis, and compared values against normal control subjects.
LDL/VLDL-associated TFPI was significantly elevated in hyperlipidemic patients compared with controls (0.383±0.112 vs 0.237±0.077 U/mL) and correlated positively with plasma cholesterol levels.
Free TFPI was significantly lower in hyperlipidemic patients than in controls (0.381±0.132 vs 0.495±0.106 U/mL) and correlated negatively with cholesterol levels.
Patients receiving plasmapheresis exhibited an even larger reduction in free TFPI (0.271±0.089 U/mL) due to the ongoing removal of lipoprotein- and endothelial cell–associated TFPI pools.

Structured PICO

Population

19 hyperlipidemic patients (including some receiving plasmapheresis treatment) and normal control subjects

Comparator

Normal control subjects

Outcome

Levels of various forms of Tissue Factor Pathway Inhibitor (TFPI), including LDL/VLDL-associated, HDL-associated, and free formsurrogate

Hyperlipidemia is associated with increased LDL/VLDL-associated TFPI and decreased free TFPI, which may reflect reduced antithrombotic function of vascular endothelial cells.

Cite This Study

Kokawa et al. (1995) studied this question.

synapsesocial.com/papers/6a7564d1f2cd31a1fadc0bb5 https://doi.org/10.1161/01.atv.15.4.504

View Full Paper

Ask AI

Bookmark

Implication

Hyperlipidemia may impair endothelial antithrombotic capacity via TFPI redistribution; hypothesis-generating and should not yet change practice.

Tissue Factor Pathway Inhibitor Activity in Human Plasma

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Tissue Factor Pathway Inhibitor Activity in Human Plasma

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider